Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care

Daniel Schneider, Giampaolo Bianchini, Denis Horgan, Stefan Michiels, Wim Witjes, Robert Hills, Juliette Plun-Favreau, Angela Brand, Mark Lawler

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

While personalised cancer medicine holds great promise, targeting therapies to the biological characteristics of patients is limited by the number of validated biomarkers currently available. The implementation of biomarkers has undergone many challenges with few biomarkers reaching cancer patients in the clinic. There have been many biomarkers that have been published and claimed to be therapeutically useful, but few become part of the clinical decision-making process due to technical, validation and market access issues. To reduce this attrition rate, there is a significant need for policy makers and reimbursement agencies to define specific evidence requirements for the introduction of biomarkers into clinical practice. Once these requirements are more clearly defined, in an analogous manner to pharmaceuticals, researchers and diagnostic companies can better focus their biomarker research and development on meeting these specific requirements, which should lead to the more rapid introduction of new molecular oncology tests for patient benefit.

Original languageEnglish
Pages (from-to)349-358
Number of pages10
JournalPublic Health Genomics
Volume18
Issue number6
DOIs
Publication statusPublished - 01-12-2015

Fingerprint

Molecular Pathology
Biomarkers
Neoplasms
Precision Medicine
Biological Therapy
Tumor Biomarkers
Administrative Personnel
Research Personnel
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Genetics(clinical)

Cite this

Schneider, D., Bianchini, G., Horgan, D., Michiels, S., Witjes, W., Hills, R., ... Lawler, M. (2015). Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics, 18(6), 349-358. https://doi.org/10.1159/000441556
Schneider, Daniel ; Bianchini, Giampaolo ; Horgan, Denis ; Michiels, Stefan ; Witjes, Wim ; Hills, Robert ; Plun-Favreau, Juliette ; Brand, Angela ; Lawler, Mark. / Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. In: Public Health Genomics. 2015 ; Vol. 18, No. 6. pp. 349-358.
@article{d861971d96fd49c18863763c0549dd01,
title = "Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care",
abstract = "While personalised cancer medicine holds great promise, targeting therapies to the biological characteristics of patients is limited by the number of validated biomarkers currently available. The implementation of biomarkers has undergone many challenges with few biomarkers reaching cancer patients in the clinic. There have been many biomarkers that have been published and claimed to be therapeutically useful, but few become part of the clinical decision-making process due to technical, validation and market access issues. To reduce this attrition rate, there is a significant need for policy makers and reimbursement agencies to define specific evidence requirements for the introduction of biomarkers into clinical practice. Once these requirements are more clearly defined, in an analogous manner to pharmaceuticals, researchers and diagnostic companies can better focus their biomarker research and development on meeting these specific requirements, which should lead to the more rapid introduction of new molecular oncology tests for patient benefit.",
author = "Daniel Schneider and Giampaolo Bianchini and Denis Horgan and Stefan Michiels and Wim Witjes and Robert Hills and Juliette Plun-Favreau and Angela Brand and Mark Lawler",
year = "2015",
month = "12",
day = "1",
doi = "10.1159/000441556",
language = "English",
volume = "18",
pages = "349--358",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "6",

}

Schneider, D, Bianchini, G, Horgan, D, Michiels, S, Witjes, W, Hills, R, Plun-Favreau, J, Brand, A & Lawler, M 2015, 'Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care', Public Health Genomics, vol. 18, no. 6, pp. 349-358. https://doi.org/10.1159/000441556

Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. / Schneider, Daniel; Bianchini, Giampaolo; Horgan, Denis; Michiels, Stefan; Witjes, Wim; Hills, Robert; Plun-Favreau, Juliette; Brand, Angela; Lawler, Mark.

In: Public Health Genomics, Vol. 18, No. 6, 01.12.2015, p. 349-358.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care

AU - Schneider, Daniel

AU - Bianchini, Giampaolo

AU - Horgan, Denis

AU - Michiels, Stefan

AU - Witjes, Wim

AU - Hills, Robert

AU - Plun-Favreau, Juliette

AU - Brand, Angela

AU - Lawler, Mark

PY - 2015/12/1

Y1 - 2015/12/1

N2 - While personalised cancer medicine holds great promise, targeting therapies to the biological characteristics of patients is limited by the number of validated biomarkers currently available. The implementation of biomarkers has undergone many challenges with few biomarkers reaching cancer patients in the clinic. There have been many biomarkers that have been published and claimed to be therapeutically useful, but few become part of the clinical decision-making process due to technical, validation and market access issues. To reduce this attrition rate, there is a significant need for policy makers and reimbursement agencies to define specific evidence requirements for the introduction of biomarkers into clinical practice. Once these requirements are more clearly defined, in an analogous manner to pharmaceuticals, researchers and diagnostic companies can better focus their biomarker research and development on meeting these specific requirements, which should lead to the more rapid introduction of new molecular oncology tests for patient benefit.

AB - While personalised cancer medicine holds great promise, targeting therapies to the biological characteristics of patients is limited by the number of validated biomarkers currently available. The implementation of biomarkers has undergone many challenges with few biomarkers reaching cancer patients in the clinic. There have been many biomarkers that have been published and claimed to be therapeutically useful, but few become part of the clinical decision-making process due to technical, validation and market access issues. To reduce this attrition rate, there is a significant need for policy makers and reimbursement agencies to define specific evidence requirements for the introduction of biomarkers into clinical practice. Once these requirements are more clearly defined, in an analogous manner to pharmaceuticals, researchers and diagnostic companies can better focus their biomarker research and development on meeting these specific requirements, which should lead to the more rapid introduction of new molecular oncology tests for patient benefit.

UR - http://www.scopus.com/inward/record.url?scp=84952872394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952872394&partnerID=8YFLogxK

U2 - 10.1159/000441556

DO - 10.1159/000441556

M3 - Article

C2 - 26571110

AN - SCOPUS:84952872394

VL - 18

SP - 349

EP - 358

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 6

ER -

Schneider D, Bianchini G, Horgan D, Michiels S, Witjes W, Hills R et al. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics. 2015 Dec 1;18(6):349-358. https://doi.org/10.1159/000441556